Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMD 525797 in mCRPC
NCT01360840Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Apr 2011
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of abituzumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by EMD Serono. Started Apr 2011; status: completed.
02
Drugs
abituzumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01360840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360840.